Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$1.97	$1.56	$0.95 ▼ $2.99	$17.68M	0.05	367,479 shs	140,668 shs
NRBO NeuroBo Pharmaceuticals	$0.70 +1.2%	$0.78	$2.08 ▼ $5.30	$6.03M	-0.26	52,006 shs	34,797 shs
RVPH Reviva Pharmaceuticals	$0.67 -6.4%	$0.84	$0.49 ▼ $4.28	$31.50M	0.11	1.16 million shs	790,360 shs
UNCY Unicycive Therapeutics	$0.67 -2.8%	$0.63	$2.02 ▼ $11.00	$84.38M	2.01	204,635 shs	7.57 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	+1.03%	-2.96%	+58.87%	-30.88%
NRBO NeuroBo Pharmaceuticals	+1.16%	-9.68%	+0.14%	-54.84%	-81.77%
RVPH Reviva Pharmaceuticals	0.00%	-13.59%	-35.19%	-35.19%	-50.80%
UNCY Unicycive Therapeutics	0.00%	+4.64%	+11.25%	-1.84%	+3.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYTU Aytu BioPharma	1.28 of 5 stars	0.0	4.0	0.0	3.4	2.4	0.0	0.6
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	2.1554 of 5 stars	3.6	1.0	0.0	0.0	0.6	3.3	0.6
UNCY Unicycive Therapeutics	3.5682 of 5 stars	3.8	5.0	0.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	0.00	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	0.00	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	3.29	Buy	$9.00	1,235.31% Upside
UNCY Unicycive Therapeutics	3.50	Strong Buy	$6.00	798.88% Upside

Current Analyst Ratings Breakdown

Latest NRBO, UNCY, AYTU, and RVPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$9.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
4/24/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/21/2025	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
4/11/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/1/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.00
4/1/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.50

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$81M	0.22	N/A	N/A	$4.64 per share	0.42
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	$1.50 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A
UNCY Unicycive Therapeutics	$680K	124.09	N/A	N/A	$0.07 per share	9.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	N/A
NRBO NeuroBo Pharmaceuticals	-$12.47M	N/A	0.00	N/A	N/A	N/A	-189.12%	-122.31%	8/12/2025 (Estimated)
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.79	N/A	N/A	N/A	N/A	N/A	-302.31%	8/13/2025 (Estimated)
UNCY Unicycive Therapeutics	-$36.73M	-$0.51	N/A	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest NRBO, UNCY, AYTU, and RVPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A
5/14/2025	Q3 2025	AYTU Aytu BioPharma	-$0.17	$0.20	+$0.37	$0.21	$13.74 million	$18.45 million
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$0.14	-$0.05	+$0.09	-$0.05	N/A	N/A
3/31/2025	Q4 2024	RVPH Reviva Pharmaceuticals	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
3/27/2025	Q4 2024	UNCY Unicycive Therapeutics	-$0.13	-$0.26	-$0.13	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.03	0.87
NRBO NeuroBo Pharmaceuticals	N/A	2.41	2.41
RVPH Reviva Pharmaceuticals	N/A	0.54	0.54
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
NRBO NeuroBo Pharmaceuticals	1.37%
RVPH Reviva Pharmaceuticals	63.18%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	3.60%
NRBO NeuroBo Pharmaceuticals	1.05%
RVPH Reviva Pharmaceuticals	27.18%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	8.98 million	5.95 million	Not Optionable
NRBO NeuroBo Pharmaceuticals	10	8.62 million	8.53 million	Not Optionable
RVPH Reviva Pharmaceuticals	5	46.74 million	34.04 million	Optionable
UNCY Unicycive Therapeutics	9	126.41 million	112.87 million	Not Optionable

NRBO, UNCY, AYTU, and RVPH Headlines

Recent News About These Companies

Unicycive Therapeutics Inc trading halted, news pending

June 19 at 12:42 AM | msn.com

Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing

June 18 at 7:40 PM | investing.com

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

June 17 at 7:00 AM | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in May

June 15, 2025 | marketbeat.com

Brookline Capital Management Weighs in on UNCY Q3 Earnings

June 14, 2025 | americanbankingnews.com

UNCY Q3 EPS Forecast Raised by Brookline Capital Management

June 12, 2025 | marketbeat.com

Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations

June 11, 2025 | theglobeandmail.com

Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m

June 11, 2025 | finance.yahoo.com

Unicycive Shares Slide as FDA Flags Issues Related to Kidney Drug Application

June 10, 2025 | marketwatch.com

Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues

June 10, 2025 | investing.com

Unicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025

June 10, 2025 | quiverquant.com

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

June 10, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short Interest

June 3, 2025 | marketbeat.com

What is HC Wainwright's Estimate for UNCY Q2 Earnings?

May 30, 2025 | marketbeat.com

Q4 Earnings Estimate for UNCY Issued By HC Wainwright

May 29, 2025 | marketbeat.com

Unicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC Wainwright

May 28, 2025 | marketbeat.com

Unicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor Conferences

May 22, 2025 | quiverquant.com

Unicycive Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025 | globenewswire.com

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Q2 Earnings Forecast for UNCY Issued By Noble Financial

May 20, 2025 | marketbeat.com

Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRBO, UNCY, AYTU, and RVPH Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$1.97 0.00 (0.00%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.98 +0.02 (+0.76%)

As of 06/18/2025 07:55 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.70 +0.01 (+1.16%)

As of 06/18/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.67 -0.05 (-6.39%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.69 +0.02 (+2.82%)

As of 06/18/2025 07:49 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Unicycive Therapeutics NASDAQ:UNCY

$0.67 -0.02 (-2.80%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.64 -0.03 (-4.87%)

As of 06/18/2025 07:49 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time